Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Strong
Earnings
Neutral
Dividends
Very Weak
Capital Efficiency
Very Strong
Balance Sheet
Very Weak
Website
Larimar Therapeutics, Inc.
Telephone
1.844.511.9056
Address
Suite 506, Three Bala Plaza East, Bala Cynwyd, PA 19004
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.8 - 6.42
Trade Value (12mth)
US$2,529,344.00
1 week
-6.98%
1 month
-27.13%
YTD
-4.03%
1 year
72.54%
All time high
664.32
EPS 3 yr Growth
64.90%
EBITDA Margin
0.00%
Operating Cashflow
-$113m
Free Cash Flow Return
-88.10%
ROIC
-129.00%
Interest Coverage
0.00
Quick Ratio
2.20
Shares Outstanding (Fully Diluted)
90m
HALO Sector
Healthcare
Next Company Report Date
19-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 20 May 26 | |
| 20 May 26 | |
| 15 May 26 | |
| 15 May 26 | |
| 15 May 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -0.84 | -1.32 | -2.26 | | | | ||
EPS (Fully Diluted) | $ | | | | | -0.84 | -1.32 | -2.26 | | | | ||
Growth | % | | | | | 38.7 | -56.3 | -72 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
